secwatch.observer — SEC 8-K summary
======================================

Issuer:     Caribou Biosciences, Inc. (CRBU)
CIK:        0001619856
Form:       8-K
Filed at:   2023-07-06T23:59:59+00:00
Accession:  0001619856-23-000079
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 1.01, 3.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pfizer invests $25M in Caribou at $5.33/sh; gains SAB seat & BCMA first negotiation rights
--------------------------------------------------------------------------------

- Pfizer purchased 4,690,431 shares at $5.33/sh for ~$25M; deal closed June 30, 2023.
- Proceeds must be used for CB-011 (anti-BCMA CAR-T) development over 36 months.
- Pfizer gets 30-day right of first negotiation for commercialization rights on BCMA candidates.
- Pfizer's Sriram Krishnaswami, PhD, joins Caribou's Scientific Advisory Board.
- Caribou retains full ownership/control of its allogeneic CAR-T and CAR-NK pipeline.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1619856/000161985623000079/0001619856-23-000079-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1619856/000161985623000079/crbu-20230629.htm
  HTML page:      https://secwatch.observer/filing/0001619856-23-000079

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer